[go: up one dir, main page]

WO2021048564A3 - Domaine de liaison à l'antigène - Google Patents

Domaine de liaison à l'antigène Download PDF

Info

Publication number
WO2021048564A3
WO2021048564A3 PCT/GB2020/052199 GB2020052199W WO2021048564A3 WO 2021048564 A3 WO2021048564 A3 WO 2021048564A3 GB 2020052199 W GB2020052199 W GB 2020052199W WO 2021048564 A3 WO2021048564 A3 WO 2021048564A3
Authority
WO
WIPO (PCT)
Prior art keywords
antigen
binding domain
cars
present
binding domains
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/GB2020/052199
Other languages
English (en)
Other versions
WO2021048564A2 (fr
Inventor
Martin PULÉ
Shaun CORDOBA
Simon Thomas
Shimobi ONUOHA
Ram JHA
Mathieu FERRARI
Alex KINNA
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Autolus Ltd
Original Assignee
Autolus Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Autolus Ltd filed Critical Autolus Ltd
Publication of WO2021048564A2 publication Critical patent/WO2021048564A2/fr
Publication of WO2021048564A3 publication Critical patent/WO2021048564A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La présente invention concerne des domaines de liaison à l'antigène qui se lient au récepteur orphelin 1 de type tyrosine kinase (ROR1). La présente invention concerne également des récepteurs antigéniques chimériques (CAR) comprenant de tels domaines de liaison à l'antigène, des cellules comprenant de tels CAR et leur utilisation pour traiter le cancer.
PCT/GB2020/052199 2019-09-13 2020-09-11 Domaine de liaison à l'antigène Ceased WO2021048564A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB201913258A GB201913258D0 (en) 2019-09-13 2019-09-13 Antigen-binding domain
GB1913258.8 2019-09-13

Publications (2)

Publication Number Publication Date
WO2021048564A2 WO2021048564A2 (fr) 2021-03-18
WO2021048564A3 true WO2021048564A3 (fr) 2021-04-22

Family

ID=68315378

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2020/052199 Ceased WO2021048564A2 (fr) 2019-09-13 2020-09-11 Domaine de liaison à l'antigène

Country Status (2)

Country Link
GB (1) GB201913258D0 (fr)
WO (1) WO2021048564A2 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2022227686A1 (en) 2021-02-25 2023-07-27 Lyell Immunopharma, Inc. Ror1 targeting chimeric antigen receptor
WO2023077026A1 (fr) 2021-10-28 2023-05-04 Lyell Immunopharma, Inc. Procédés de culture de cellules exprimant une protéine de liaison à ror1
CN119421897A (zh) * 2022-07-06 2025-02-11 诺纳生物（苏州）有限公司 抗ror1抗体
WO2024064958A1 (fr) 2022-09-23 2024-03-28 Lyell Immunopharma, Inc. Procédés de culture de cellules déficientes en nr4a
WO2024064952A1 (fr) 2022-09-23 2024-03-28 Lyell Immunopharma, Inc. Procédés de culture de cellules déficientes en nr4a surexprimant c-jun
WO2024077174A1 (fr) 2022-10-05 2024-04-11 Lyell Immunopharma, Inc. Procédés de culture de cellules déficientes en nr4a
WO2025217398A1 (fr) 2024-04-10 2025-10-16 Lyell Immunopharma, Inc. Procédés de culture de cellules avec milieu de culture amélioré

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016187216A1 (fr) * 2015-05-18 2016-11-24 Bluebird Bio, Inc. Récepteurs antigéniques chimériques anti-ror1

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201206559D0 (en) 2012-04-13 2012-05-30 Ucl Business Plc Polypeptide
GB201405845D0 (en) 2014-04-01 2014-05-14 Ucl Business Plc Signalling system
GB201415347D0 (en) 2014-08-29 2014-10-15 Ucl Business Plc Signalling system
GB201501936D0 (en) 2015-02-05 2015-03-25 Ucl Business Plc Signalling system
GB201503133D0 (en) 2015-02-24 2015-04-08 Ucl Business Plc And Syncona Partners Llp Chimeric protein

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016187216A1 (fr) * 2015-05-18 2016-11-24 Bluebird Bio, Inc. Récepteurs antigéniques chimériques anti-ror1

Also Published As

Publication number Publication date
WO2021048564A2 (fr) 2021-03-18
GB201913258D0 (en) 2019-10-30

Similar Documents

Publication Publication Date Title
WO2021048564A3 (fr) Domaine de liaison à l'antigène
MX2019015352A (es) Linfocitos t con receptor de antigeno quimerico (car) para receptor 1 huerfano tipo receptor de tirosina cinasa (ror 1).
ZA202101495B (en) Chimeric antigen receptor
PH12021551676A1 (en) Gprc5d chimeric antigen receptors and cells expressing the same
MX2024007724A (es) Conjugados de farmaco-anticuerpo anti-antigeno de membrana especifico de prostata (psma) humanizado
WO2019241358A3 (fr) Récepteurs antigéniques chimériques bispécifiques à chaîne unique pour le traitement du cancer
MX2024015844A (es) Anticuerpos agonistas que se unen a cd137 humano y sus usos
WO2020016662A3 (fr) Anticorps spécifiques de l'antigène trophoblaste 2 (trop2)
MX392369B (es) Anticuerpos anti-ilt4 y fragmentos de union a antigeno.
PH12020551689A1 (en) Her2-targeting antigen binding molecules comprising 4-1bbl
PH12018501554A1 (en) Ror1 antibody compositions and related methods
PH12019502637A1 (en) Chimeric antigen receptors targeting flt3
PH12021551500A1 (en) Anti-ctla4 antibodies and methods of use thereof
MX2020006818A (es) Receptores quimericos multiespecificos que comprenden un dominio nkg2d, y metodos de uso de los mismos.
EP4559928A3 (fr) Commutateurs de cellules effectrices de récepteur d'antigène chimérique avec fractions de ciblage humanisées et/ou domaines d'interaction de récepteur d'antigène chimérique
EA201990208A1 (ru) Химерные антигенные рецепторы, нацеленные на bcma, и способы их применения
WO2016164731A8 (fr) Thérapies anti-cd20, thérapies anti-cd22, et polythérapies comprenant une cellule exprimant le récepteur antigénique chimérique (car) dirigé contre le cd19
EA202091982A1 (ru) Химерный антигенный рецептор к рецептору il-13 альфа 2 (il13r2) для опухолеспецифической т-клеточной иммунотерапии
MX2011009312A (es) Formulaciones de anticuerpos humanizados anti-cd19.
EP4527466A3 (fr) Récepteurs antigéniques chimériques anti-dll3 et leurs utilisations
WO2021127200A8 (fr) Agents de liaison à ilt3 et leurs méthodes d'utilisation
CL2018003608A1 (es) Anticuerpo aislado o fragmento de unión a antígeno del mismo que se une específicamente interleucina-25 hjumana (il-2525); composición farmacéutica que lo comprende; uso de dicha composición farmacéutica para tratar una enfermedad o trastorno asociado con la actividad o expresión de il-25. (divisional solicitud 201700703)
WO2020106461A3 (fr) Anticorps anti-mertk et leurs méthodes d'utilisation
MX2024007390A (es) Anticuerpo completamente humanizado y receptor de antigeno quimerico (car) dirigido al subtipo d de la familia c5 del receptor acoplado a proteina g (gprc5d) y usos del mismo.
PH12021552379A1 (en) Anti-egfrviii antibodies and antigen-binding fragments thereof

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 20772401

Country of ref document: EP

Kind code of ref document: A2